Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2023	Sep. 30, 2022
Current assets:
Cash, cash equivalents and restricted cash	$ 105,334	$ 108,005
Accounts receivable	1,247	1,410
Short term investments	346,369	268,391
Prepaid expenses	10,053	7,289
Other current assets	7,162	20,204
Total current assets	470,165	405,299
Property and equipment, net	231,369	110,297
Intangible assets, net	10,687	11,962
Long-term investments	42,758	105,872
Right-of-use assets	40,667	58,291
Other assets	210	218
Total Assets	795,856	691,939
Current liabilities:
Accounts payable	7,874	2,868
Accrued expenses	38,191	46,856
Accrued payroll and benefits	4,434	12,251
Lease liabilities	2,823	2,776
Deferred revenue	16,905	74,099
Total current liabilities	70,227	138,850
Long-term liabilities:
Lease liabilities, net of current portion	79,911	78,800
Deferred revenue, net of current portion	0	55,950
Liability related to the sale of future royalties	263,064	0
Other liabilities	669	0
Total long-term liabilities	343,644	134,750
Commitments and contingencies (Note 7)
Noncontrolling interest and stockholders’ equity:
Common stock, $0.001 par value: Authorized 290,000 and 145,000 shares; issued and outstanding 107,102 and 105,960 shares	199	198
Additional paid-in capital	1,281,393	1,219,213
Accumulated other comprehensive loss	(411)	(136)
Accumulated deficit	(916,351)	(820,755)
Total Arrowhead Pharmaceuticals, Inc. stockholders’ equity	364,830	398,520
Noncontrolling interest	17,155	19,819
Total noncontrolling interest and stockholders’ equity	381,985	418,339
Total Liabilities, Noncontrolling Interest and Stockholders’ Equity	$ 795,856	$ 691,939